• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿帕替尼联合拓扑替康用于铂耐药复发性卵巢癌患者的多线治疗：三例报告

Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases.

作者信息

Cheng Yuan, Zhang Juan, Geng Haiyun, Qin Shukui, Hua Haiqing

机构信息

Department of Medical Oncology, People's Liberation Army Cancer Center, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, Nanjing, China.

出版信息

Onco Targets Ther. 2018 Apr 6;11:1989-1995. doi: 10.2147/OTT.S158141. eCollection 2018.

DOI:10.2147/OTT.S158141
PMID:29670374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5898585/
Abstract

The aim of this study was to observe the efficacy and safety of apatinib combined with toptecan therapy in the multiline treatment of platinum-resistant recurrent ovarian cancer patients. The clinical records of three patients with platinum-resistant recurrent ovarian cancer treated with apatinib combined with toptecan therapy were analyzed and followed up for 3 months, and the related literatures were reviewed. The three patients achieved partial response and the tumor marker CA125 levels decreased significantly as an outcome of the treatment. Major adverse reactions were hypertension, hand-foot skin reaction, and anemia, which were manageable with medication. Apatinib combined with toptecan multiline therapy in the treatment of platinum-resistant recurrent ovarian cancer patients is effective, and the adverse effects are tolerated. Large-scale studies should be conducted to further determine the efficacy and safety of this treatment protocol.

摘要

本研究旨在观察阿帕替尼联合拓扑替康治疗铂耐药复发性卵巢癌患者多线治疗的疗效和安全性。分析了3例接受阿帕替尼联合拓扑替康治疗的铂耐药复发性卵巢癌患者的临床记录，并进行了3个月的随访，并复习了相关文献。3例患者均获得部分缓解，治疗后肿瘤标志物CA125水平显著下降。主要不良反应为高血压、手足皮肤反应和贫血，可通过药物控制。阿帕替尼联合拓扑替康多线治疗铂耐药复发性卵巢癌患者有效，且不良反应可耐受。应开展大规模研究以进一步确定该治疗方案的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/4890facdcc28/ott-11-1989Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/aae06ae7c9fd/ott-11-1989Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/a5c0c2b60211/ott-11-1989Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/12468fcafd5e/ott-11-1989Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/4890facdcc28/ott-11-1989Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/aae06ae7c9fd/ott-11-1989Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/a5c0c2b60211/ott-11-1989Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/12468fcafd5e/ott-11-1989Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce5/5898585/4890facdcc28/ott-11-1989Fig4.jpg

相似文献

1
Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases.阿帕替尼联合拓扑替康用于铂耐药复发性卵巢癌患者的多线治疗：三例报告
Onco Targets Ther. 2018 Apr 6;11:1989-1995. doi: 10.2147/OTT.S158141. eCollection 2018.
2
Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.阿帕替尼联合依托泊苷治疗铂耐药复发性上皮性卵巢癌患者的疗效和安全性：一项回顾性研究
J Cancer. 2020 Jul 9;11(18):5353-5358. doi: 10.7150/jca.45547. eCollection 2020.
3
Efficacy and safety of apatinib in the treatment of patients with platinum‑resistant ovarian cancer: A systematic review and network meta‑analysis.阿帕替尼治疗铂耐药卵巢癌患者的疗效与安全性：一项系统评价和网状Meta分析
Exp Ther Med. 2024 Jul 26;28(4):376. doi: 10.3892/etm.2024.12665. eCollection 2024 Oct.
4
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.阿帕替尼联合依托泊苷口服治疗铂耐药或铂抵抗复发性卵巢癌（AEROC）的Ⅱ期、单臂、前瞻性研究。
Lancet Oncol. 2018 Sep;19(9):1239-1246. doi: 10.1016/S1470-2045(18)30349-8. Epub 2018 Aug 3.
5
A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.阿帕替尼治疗复发性上皮性卵巢癌的 II 期研究。
Gynecol Oncol. 2018 Feb;148(2):286-290. doi: 10.1016/j.ygyno.2017.12.013. Epub 2017 Dec 18.
6
Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment.阿帕替尼疗效的真实世界数据——多线治疗预处理的转移性乳腺癌患者回顾性研究结果
Front Oncol. 2021 Jun 10;11:643654. doi: 10.3389/fonc.2021.643654. eCollection 2021.
7
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.索拉非尼联合拓扑替康对比安慰剂联合拓扑替康治疗铂耐药卵巢癌（TRIAS）：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。
Lancet Oncol. 2018 Sep;19(9):1247-1258. doi: 10.1016/S1470-2045(18)30372-3. Epub 2018 Aug 9.
8
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.一项开放标签、随机、二期临床试验，旨在评估在先前接受贝伐珠单抗一线或铂类敏感卵巢癌治疗的铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌患者中，标准治疗联合或不联合贝伐珠单抗的疗效和安全性：日本妇科肿瘤学组研究 JGOG3023 的原理、设计和方法。
BMC Cancer. 2018 Jul 31;18(1):771. doi: 10.1186/s12885-018-4505-4.
9
[Clinical observation of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer].甲磺酸阿帕替尼治疗多药耐药晚期乳腺癌的临床观察
Zhonghua Yi Xue Za Zhi. 2018 Apr 24;98(16):1246-1249. doi: 10.3760/cma.j.issn.0376-2491.2018.16.012.
10
Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.卡巴他赛 - 复发性铂耐药卵巢癌的治疗选择。
Anticancer Res. 2020 Sep;40(9):5255-5261. doi: 10.21873/anticanres.14529.

引用本文的文献

1
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.阿帕替尼治疗能有效延缓仅有生化复发的卵巢癌进展。
J Ovarian Res. 2021 Jul 12;14(1):91. doi: 10.1186/s13048-021-00843-8.
2
Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells.阿帕替尼，一种新型的酪氨酸激酶抑制剂，通过 Nrf2/HO-1 通路促进卵巢癌细胞中 ROS 依赖的细胞凋亡和自噬。
Oxid Med Cell Longev. 2020 May 13;2020:3145182. doi: 10.1155/2020/3145182. eCollection 2020.
3
Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review.

本文引用的文献

1
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.鲁卡帕利治疗复发铂类敏感型高级别卵巢癌（ARIEL2 研究第 1 部分）：一项国际多中心、开放标签、2 期临床试验。
Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.
2
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.帕唑帕尼联合每周紫杉醇与单独每周紫杉醇治疗铂耐药或铂难治性晚期卵巢癌（MITO 11）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14.
3
阿帕替尼单药治疗复发性卵巢癌的长期无进展生存：一例病例报告及文献综述
Onco Targets Ther. 2019 May 15;12:3635-3644. doi: 10.2147/OTT.S198946. eCollection 2019.
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
奥拉帕利单药治疗携带胚系 BRCA1/2 突变的晚期癌症患者。
J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.
4
Incorporation of pazopanib in maintenance therapy of ovarian cancer.将帕唑帕尼纳入卵巢癌维持治疗。
J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.
5
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.抗血管生成素治疗复发性卵巢癌（TRINOVA-1）：一项随机、多中心、双盲、安慰剂对照的 3 期试验。
Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.
6
Molecular implication of ADAM-15 and -17 in intrauterine adhesions.ADAM-15 和 -17 在宫腔粘连中的分子作用。
Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):264-9. doi: 10.1016/j.ejogrb.2013.06.036. Epub 2013 Aug 1.
7
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.对妇科肿瘤学组研究 0218 的独立放射学评估，这是一项贝伐珠单抗用于晚期上皮性卵巢癌、原发性腹膜癌或输卵管癌初始治疗的 III 期临床试验。
Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.
8
A phase 3 trial of bevacizumab in ovarian cancer.贝伐珠单抗治疗卵巢癌的 III 期临床试验。
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
9
Incorporation of bevacizumab in the primary treatment of ovarian cancer.贝伐珠单抗在卵巢癌初始治疗中的应用。
N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.
10
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).一项评估拓扑替康两种方案在复发性铂类敏感卵巢癌、输卵管癌或原发性腹膜癌中的疗效的 II 期研究：一项妇科肿瘤学组研究（GOG 146Q）。
Gynecol Oncol. 2011 Mar;120(3):454-8. doi: 10.1016/j.ygyno.2010.11.008. Epub 2010 Dec 17.